Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein
Abstract Virus-like particles (VLPs) are an established vaccine platform and can be strong immunogens capable of eliciting both humoral and cellular immune responses against a range of pathogens. Here, we show by cryo-electron microscopy that VLPs of Mayaro virus, which contain envelope glycoprotein...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-12-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-024-01021-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849699089551196160 |
|---|---|
| author | Young Chan Kim Yasunori Watanabe Arlen-Celina Lücke Xiyong Song Raquel de Oliveira Souza Robert Stass Sasha R. Azar Shannan L. Rossi Carla Claser Beate Mareike Kümmerer Max Crispin Thomas A. Bowden Juha T. Huiskonen Arturo Reyes-Sandoval |
| author_facet | Young Chan Kim Yasunori Watanabe Arlen-Celina Lücke Xiyong Song Raquel de Oliveira Souza Robert Stass Sasha R. Azar Shannan L. Rossi Carla Claser Beate Mareike Kümmerer Max Crispin Thomas A. Bowden Juha T. Huiskonen Arturo Reyes-Sandoval |
| author_sort | Young Chan Kim |
| collection | DOAJ |
| description | Abstract Virus-like particles (VLPs) are an established vaccine platform and can be strong immunogens capable of eliciting both humoral and cellular immune responses against a range of pathogens. Here, we show by cryo-electron microscopy that VLPs of Mayaro virus, which contain envelope glycoproteins E1-E2 and capsid, exhibit an architecture that closely resembles native virus. In contrast to monomeric and soluble envelope 2 (E2) glycoprotein, both VLPs as well as the adenovirus and modified vaccinia virus Ankara (MVA) vaccine platforms expressing the equivalent envelope glycoproteins E1-E2, and capsid induced highly neutralising antibodies after immunisation. The levels of neutralising antibodies elicited by the viral-vectored vaccines of structural proteins and VLPs increased significantly upon boosting. Immunisation of Mayaro virus VLPs in mice with or without an adjuvant (poly:IC) yielded similar levels of neutralising antibodies suggesting that the VLPs may be used for immunisation without the need for an adjuvant. A single or two doses of non-adjuvanted 5 µg of MAYV VLP vaccination provided significant protection against viremia and MAYV-induced foot swelling in the C57BL/6 mouse challenge model. MAYV VLPs represent a non-infectious vaccine candidate, which may constitute a complementary option for future immunisation strategies against this important emerging alphavirus. |
| format | Article |
| id | doaj-art-f627b3457b3f428e9321dc4ba98941aa |
| institution | DOAJ |
| issn | 2059-0105 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Vaccines |
| spelling | doaj-art-f627b3457b3f428e9321dc4ba98941aa2025-08-20T03:18:42ZengNature Portfolionpj Vaccines2059-01052024-12-019111310.1038/s41541-024-01021-9Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoproteinYoung Chan Kim0Yasunori Watanabe1Arlen-Celina Lücke2Xiyong Song3Raquel de Oliveira Souza4Robert Stass5Sasha R. Azar6Shannan L. Rossi7Carla Claser8Beate Mareike Kümmerer9Max Crispin10Thomas A. Bowden11Juha T. Huiskonen12Arturo Reyes-Sandoval13Department of Paediatrics, Oxford Vaccine Group, University of OxfordDivision of Structural Biology, Wellcome Centre for Human Genetics, University of OxfordInstitute of Virology, Medical Faculty, University of BonnInstitute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of HelsinkiDepartment of Parasitology, Institute of Biomedical Sciences, University of São PauloDivision of Structural Biology, Wellcome Centre for Human Genetics, University of OxfordDepartment of Pathology and the Institute for Human Infection and Immunity, University of Texas Medical BranchDepartment of Pathology and the Institute for Human Infection and Immunity, University of Texas Medical BranchDepartment of Parasitology, Institute of Biomedical Sciences, University of São PauloInstitute of Virology, Medical Faculty, University of BonnSchool of Biological Sciences, University of SouthamptonDivision of Structural Biology, Wellcome Centre for Human Genetics, University of OxfordInstitute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of HelsinkiInstituto Politécnico Nacional, IPN. Av. Luis Enrique Erro s/n. Unidad Adolfo López MateosAbstract Virus-like particles (VLPs) are an established vaccine platform and can be strong immunogens capable of eliciting both humoral and cellular immune responses against a range of pathogens. Here, we show by cryo-electron microscopy that VLPs of Mayaro virus, which contain envelope glycoproteins E1-E2 and capsid, exhibit an architecture that closely resembles native virus. In contrast to monomeric and soluble envelope 2 (E2) glycoprotein, both VLPs as well as the adenovirus and modified vaccinia virus Ankara (MVA) vaccine platforms expressing the equivalent envelope glycoproteins E1-E2, and capsid induced highly neutralising antibodies after immunisation. The levels of neutralising antibodies elicited by the viral-vectored vaccines of structural proteins and VLPs increased significantly upon boosting. Immunisation of Mayaro virus VLPs in mice with or without an adjuvant (poly:IC) yielded similar levels of neutralising antibodies suggesting that the VLPs may be used for immunisation without the need for an adjuvant. A single or two doses of non-adjuvanted 5 µg of MAYV VLP vaccination provided significant protection against viremia and MAYV-induced foot swelling in the C57BL/6 mouse challenge model. MAYV VLPs represent a non-infectious vaccine candidate, which may constitute a complementary option for future immunisation strategies against this important emerging alphavirus.https://doi.org/10.1038/s41541-024-01021-9 |
| spellingShingle | Young Chan Kim Yasunori Watanabe Arlen-Celina Lücke Xiyong Song Raquel de Oliveira Souza Robert Stass Sasha R. Azar Shannan L. Rossi Carla Claser Beate Mareike Kümmerer Max Crispin Thomas A. Bowden Juha T. Huiskonen Arturo Reyes-Sandoval Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein npj Vaccines |
| title | Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein |
| title_full | Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein |
| title_fullStr | Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein |
| title_full_unstemmed | Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein |
| title_short | Immunogenic recombinant Mayaro virus-like particles present natively assembled glycoprotein |
| title_sort | immunogenic recombinant mayaro virus like particles present natively assembled glycoprotein |
| url | https://doi.org/10.1038/s41541-024-01021-9 |
| work_keys_str_mv | AT youngchankim immunogenicrecombinantmayaroviruslikeparticlespresentnativelyassembledglycoprotein AT yasunoriwatanabe immunogenicrecombinantmayaroviruslikeparticlespresentnativelyassembledglycoprotein AT arlencelinalucke immunogenicrecombinantmayaroviruslikeparticlespresentnativelyassembledglycoprotein AT xiyongsong immunogenicrecombinantmayaroviruslikeparticlespresentnativelyassembledglycoprotein AT raqueldeoliveirasouza immunogenicrecombinantmayaroviruslikeparticlespresentnativelyassembledglycoprotein AT robertstass immunogenicrecombinantmayaroviruslikeparticlespresentnativelyassembledglycoprotein AT sasharazar immunogenicrecombinantmayaroviruslikeparticlespresentnativelyassembledglycoprotein AT shannanlrossi immunogenicrecombinantmayaroviruslikeparticlespresentnativelyassembledglycoprotein AT carlaclaser immunogenicrecombinantmayaroviruslikeparticlespresentnativelyassembledglycoprotein AT beatemareikekummerer immunogenicrecombinantmayaroviruslikeparticlespresentnativelyassembledglycoprotein AT maxcrispin immunogenicrecombinantmayaroviruslikeparticlespresentnativelyassembledglycoprotein AT thomasabowden immunogenicrecombinantmayaroviruslikeparticlespresentnativelyassembledglycoprotein AT juhathuiskonen immunogenicrecombinantmayaroviruslikeparticlespresentnativelyassembledglycoprotein AT arturoreyessandoval immunogenicrecombinantmayaroviruslikeparticlespresentnativelyassembledglycoprotein |